Panacea Biotec has received approval from US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market a generic version of Rizatriptan Benzoate Tablet, Orally Disintegrating, 5 mg and 10 mg.
This generic is equivalent to MAXALT-MLT ODT of Merck & Co. The current annual sales for Rizatriptan Benzoate Tablet, Orally Disintegrating, 5 mg and 10 mg in the US market is around $ 60 million. Rizatriptan Benzoate is a serotonin (5-HT) 1B/11) receptor against (triptan) indicated for the acute treatment of migraine in adults and in pediatric patients.
Further, the company is planning to launch the product within first quarter of 2017 through its distribution partner in US. Recently, the company got approval of its anti-cancer formulation facility from USFDA in November, 2016.
Panacea Biotec is one of the India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: